Evidence map›Paper›PMID 42428550›Full record

ArticleMedComm2026

Concurrent Chemoradiotherapy Plus Immunotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Randomized, Single-Center, Phase II Trial of Early Tumor Regression and Pro-Inflammatory Tumor Microenvironment Remodeling.

Yuhan Sheng, Yu Chang, Yao Jiang, Shujie Wang, Ying Zhou, Minggang Peng, Xiang Kang, Yingchao Zhao

Abstract read
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuhan ShengCancer Center Hubei Key Laboratory of Precision Radiation Oncology Institute of Radiation Oncology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Yu ChangCancer Center Hubei Key Laboratory of Precision Radiation Oncology Institute of Radiation Oncology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Yao JiangCancer Center Hubei Key Laboratory of Precision Radiation Oncology Institute of Radiation Oncology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Shujie WangCancer Center Hubei Key Laboratory of Precision Radiation Oncology Institute of Radiation Oncology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Ying ZhouCancer Center Hubei Key Laboratory of Precision Radiation Oncology Institute of Radiation Oncology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Minggang PengDepartment of Obstetrics and Gynecology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Xiang KangDepartment of Obstetrics and Gynecology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Yingchao ZhaoCancer Center Hubei Key Laboratory of Precision Radiation Oncology Institute of Radiation Oncology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Concurrent chemoradiotherapy (CCRT) followed by intrauterine brachytherapy is the standard treatment for locally advanced cervical cancer (LACC), yet its efficacy is frequently constrained by an immunosuppressive tumor microenvironment (TME). This randomized, single-center, Phase II trial (

Indexed as

cervical cancerconcurrent chemoradiotherapyimmunotherapysingle‐cell RNA sequencing

Identifiers

PMID42428550
PMCPMC13346770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.